

Table S1 Characteristics of studies on t-MNs occurring after PARPi therapy

Previous study	Types of PARPi	Cancer type	All patient numbers	Number of patients diagnosed with t-MNs (%)	Previous chemotherapy
Matulonis <i>et al.</i> [2023] (15)	Niraparib	Ovarian cancer	367	14 (3.81)	Two
Marmouset <i>et al.</i> [2022] (14)	Olaparib, niraparib, rucaparib, talazoparib	Ovarian cancer	373	13 (3.49)	Two
DiSilvestro <i>et al.</i> [2023] (6)	Olaparib	Ovarian cancer	260	4 (1.54)	One
Poveda <i>et al.</i> [2021] (22)	Olaparib	Ovarian cancer	195	6 (3.08)	At least two
O'Malley <i>et al.</i> [2022] (5)	Rucaparib	Ovarian cancer	375	14 (3.73)	At least two

t-MNs, therapy-related myeloid neoplasms; PARPi, poly(ADP-ribose) polymerase inhibitor.